HENRY A. WAXMAN, CALIFORNIA
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
EDOLPHUS TOWNS, NEW YORK
RANK PALLONE, J.R., NEW JERSEY
BART GORDON, TENNESSEE
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
ALBERT R. WYNN, MARYLAND
GENE GREEN, TEXAS
DIANA DEGETTE, COLORADO
VICE CHAIRMAN
LOIS CAPPS, CALIFORNIA
MIKE DOYLE, PENSYLVANIA
JANE HARMAN, CALIFORNIA
TOM ALLEN, MAINE
JAN SCHAKOWSKY, ILLINOIS
HILDA L. SOLIS, CALIFORNIA
CHARLES A. GONZALEZ, TEXAS
JAY INSLEE, WASHINGTON
TAMMY BALDWIN, WISCONSIN
MIKE ROSS, ARKANSAS
DARLENE HOOLEY, OREGON
ANTHONY D. WEINER, NEW YORK
JIM MATHESON, UTAH
G.K. BUTTERFIELD, NORTH CAROLINA
CHARLES RELANCE, USISIANA
JOHN BARROW, GEORGIA
BARON P. HILL INDIANA

DENNIS B. FITZGIBBONS, CHIEF OF STAFF GREGG A. ROTHSCHILD, CHIEF COUNSEL ONE HUNDRED TENTH CONGRESS

U.S. House of Representatives Committee on Energy and Commerce Washington, DC 20515-6115

JOHN D. DINGELL, MICHIGAN CHAIRMAN

July 2, 2007

JOE BARTON, TEXAS
ARANKING MEMBER
RALPH M. HALL, TEXAS
J. DENNIS HASTERT, ILLINOIS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITFIELD, KENTUCKY
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BOND, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
SUE MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE

The Honorable Andrew C. von Eschenbach, M.D. Commissioner
U. S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857-0001

Dear Dr. von Eschenbach:

Under Rules X and XI of the Rules of the United States House of Representatives, the Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are investigating the ability of the Food and Drug Administration (FDA) to protect the American public from excessive risks associated with prescription drugs and unsafe food. As part of those investigations, we are examining FDA inspections of foreign manufacturing facilities, especially in China and India, that may not be adequate to protect against contaminated products entering the United States.

We have instructed the Committee staff to accompany FDA personnel in one or more inspections of drug manufacturing plants and food processing plants in both China and India. The staff expect to accompany FDA inspectors, where possible, on inspections already scheduled.

Accordingly, we request that you provide a schedule of all upcoming foreign inspections in China and India, including the names of the firms being inspected, the locations of the facilities, the types of inspection, and the proposed dates of inspection. This request should be considered effective for all potential congressional staff travel associated with foreign inspections for the balance of the 110th Congress.

The Honorable Andrew C. von Eschenbach, M.D. Page 2

Please provide the requested information as soon as possible. If you have any questions regarding these requests, please contact us or have your staff contact Chris Knauer or David Nelson of the Committee staff at (202) 226-2424.

Sincerely,

John D. Dingell

Chairman

Bart Stupak

Chairman

Subcommittee on Oversight and Investigations

cc: The Honorable Joe Barton, Ranking Member Committee on Energy and Commerce

The Honorable Ed Whitfield, Ranking Member Subcommittee on Oversight and Investigations